Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:30:57.368Z.
Calculation as of: 2026-10-06T13:30:57.368Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c0c25a561797b8251bbc96a681ec43d66f95a8f813bb62f19698de697ac6593e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$46.88M
EBITDA Yield
N/A
TTM Avg
14.45%
3Y Avg
11.70%
5Y Avg
11.70%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $49.21M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 11.15% | 20.03% | 16.76% | 21.84% |
| Clene Inc. (CLNN)vs › | $49.84M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.64M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.17M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $46.88M | N/A | 14.45% | 11.70% | 11.70% |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | N/A | 0.59% | 0.59% | 0.59% |
| INmune Bio, Inc. (INMB)vs › | $51.84M | N/A | 3.11% | 2.71% | 2.71% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.71M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
